Trust in early phase research: Therapeutic optimism and protective pessimism
Department of Psychiatry, The Bioethics Program, The Center for Behavioral and Decision Sciences in Medicine, University of Michigan, 300 North Ingalls Street, 7C27, Ann Arbor, MI, 48109, USA. Medicine Health Care and Philosophy
(Impact Factor: 0.91).
12/2008; 11(4):393-401. DOI: 10.1007/s11019-008-9153-z
Bioethicists have long been concerned that seriously ill patients entering early phase ('phase I') treatment trials are motivated by therapeutic benefit even though the likelihood of benefit is low. In spite of these concerns, consent forms for phase I studies involving seriously ill patients generally employ indeterminate benefit statements rather than unambiguous statements of unlikely benefit. This seeming mismatch between attitudes and actions suggests a need to better understand research ethics committee members' attitudes toward communication of potential benefits and risks of early phase studies to potential subjects. We surveyed the members of two U.S. research ethics committees using a phase I gene transfer study scenario, and compared the results to a previous survey of potential subjects' perceptions and attitudes toward benefit and risk for the same protocol. The results show that there is indeed a gap between the subjects' perceptions and the committee members' views on what is appropriate to be communicated to research subjects. This discrepancy is the product of both the commonly assumed optimism of the subjects and to a "protective pessimism" of the research ethics committee members. We discuss this discrepancy using "frameworks of trust" and demonstrate the need to incorporate these frameworks into the existing model of informed consent.
Available from: Shelly Benjaminy
- "Trust also mediated patient risk perspectives: patients revealed trust in science25 and trust in their physicians.27 Trust allows patients to reinterpret uncertainties in phase I trials as opportunities for potential benefits rather than as risks of harm.35 "
[Show abstract] [Hide abstract]
Ocular gene transfer clinical trials are raising patient hopes for the treatment of choroideremia – a blinding degenerative retinopathy. Phase I choroideremia gene transfer trials necessitate communicating about the risks of harm and potential benefits with patients while avoiding the sensationalism that has historically undermined this field of translational medicine.
We conducted interviews between June 2011 and June 2012 with 6 choroideremia patient advocates, 20 patients, and 15 clinicians about their hopes for benefits, perceived risks of harm, and hopes for the time frame of clinical implementation of choroideremia gene transfer.
Despite the safety focus of phase I trials, participants hoped for direct visual benefits with evident discrepancies between stakeholder perspectives about the degree of visual benefit. Clinicians and patient advocates were concerned by limited patient attention to risks of harm. Interviews revealed confusion about the time frames for the clinical implementation of choroideremia gene transfer and patient urgency to access gene transfer within a limited therapeutic window.
Differences in stakeholder perspectives about choroideremia gene transfer necessitate strategies that promote responsible communications about choroideremia gene transfer and aid in its translation. Strategies should counter historical sensationalism associated with gene transfer, promote informed consent, and honor patient hope while grounding communications in current clinical realities.
Genetics in medicine: official journal of the American College of Medical Genetics 09/2013; DOI:10.1038/gim.2013.148 · 7.33 Impact Factor
Available from: Raymond De Vries
Medicine Health Care and Philosophy 12/2008; 11(4):377-9. DOI:10.1007/s11019-008-9158-7 · 0.91 Impact Factor
The American Journal of Bioethics 03/2009; 9(2):11-2. DOI:10.1080/15265160802654228 · 5.29 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.